Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.

The Journal of clinical investigation - 15 Oct 2025

Tiedje Vera, Greenberg Jillian, Qin Tianyue, Im Soo-Yeon, Krishnamoorthy Gnana P, Boucai Laura, Xu Bin, French Jena D, Sherman Eric J, Ho Alan L, de Stanchina Elisa, Socci Nicholas D, Jin Jian, Ghossein Ronald A, Knauf Jeffrey A, Koche Richard P, Fagin James A

Abstract excerpt

Cancer cells present neoantigens dominantly through MHC class I (MHCI) to drive tumor rejection through cytotoxic CD8+ T cells. There is growing recognition that a subset of tumors express MHC class II (MHCII), causing recognition of antigens by TCRs of CD4+ T cells that contribute to the antitumor response. We found that mouse BrafV600E-driven anaplastic thyroid cancers (ATCs) responded markedly to the RAF plus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Histocompatibility Antigens Class II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to MAP Kinase Signaling System

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Thyroid Carcinoma, Anaplastic

Source

Open in PubMed Open full text

Identifiers

PMID: 40828595
DOI: 10.1172/JCI191781
PMCID: PMC12520682

Genes

CD4
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.PMID 40828595Read ↗

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.Semantic proximity Read ↗

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.Semantic proximity Read ↗

Biological Consequences of MHC-II Expression by Tumor Cells in CancerSemantic proximity Read ↗

Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid CancerSemantic proximity Read ↗

CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.Semantic proximity Read ↗

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer CellsSemantic proximity Read ↗

Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.Semantic proximity Read ↗

Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.Semantic proximity Read ↗

Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review.Semantic proximity Read ↗

A Dominant Inhibitory Mutant of the Type II Transforming Growth Factor β Receptor in the Malignant Progression of a Cutaneous T-Cell LymphomaSemantic proximity Read ↗

Delayed allograft rejection by the suppression of class II transactivator.Semantic proximity Read ↗

Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.